ProMIS Neurosciences submits IND to FDA for Alzheimer's antibody PMN310

ProMIS Neurosciences Inc.

IND filed for PMN310, a monoclonal antibody targeting toxic amyloid-beta oligomers in Alzheimer's disease.
PMN310 designed for high selectivity to toxic oligomers, potentially reducing ARIA risk vs other antibodies.
Company expects to become a clinical-stage company pending FDA clearance of the IND.
Preclinical data showed strong ex vivo target engagement and favorable in vitro comparison to other Aβ antibodies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.